Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck RotaTeq by Year
RotaTeq (rotavirus live oral pentavalent vaccine) — International reported growth YoY (%) (%)
Merck RotaTeq: 3.0% in FY2025, up 16.0 pts from a year earlier.
Latest, FY2025
3.0%
Period ended Dec 31, 2025
Change on a year earlier
+16.0 pts
-13.0% in FY2024
History
5 years
Since FY2018
Sources
5
Documents cited below
Where the FY2025 figure comes from
“|| RotaTeq | 673 | 711 | -5 | 426 | 472 | -10 | 246 | 239 | 3”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 8-K Table 3a / 3b Product Sales.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | RotaTeq (rotavirus live oral pentavalent vaccine) — International reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.0% | +16.0 pts | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | -13.0% | – | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2021 | Dec 31, 2021 | 7.0% | – | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2019 | Dec 31, 2019 | 22.0% | +8.0 pts | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2018 | Dec 31, 2018 | 14.0% | – | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
Cite this data
StockData. (2026). Merck RotaTeq (%), annual FY2018–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-rotateq-intl-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.